M
Martin J. S. Dyer
Researcher at University of Leicester
Publications - 381
Citations - 26475
Martin J. S. Dyer is an academic researcher from University of Leicester. The author has contributed to research in topics: Chronic lymphocytic leukemia & Chromosomal translocation. The author has an hindex of 85, co-authored 373 publications receiving 24909 citations. Previous affiliations of Martin J. S. Dyer include The Royal Marsden NHS Foundation Trust & Ohio State University.
Papers
More filters
Journal ArticleDOI
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Ekkehard Mössner,Peter Brünker,Samuel Moser,Ursula Püntener,Carla Schmidt,Sylvia Herter,Roger Grau,Christian Gerdes,Adam Nopora,Erwin van Puijenbroek,Claudia Ferrara,Peter Sondermann,Christiane Jäger,Pamela Strein,Georg Fertig,Thomas Friess,Christine Schüll,Sabine Bauer,Joseph Dal Porto,Christopher Del Nagro,Karim Dabbagh,Martin J. S. Dyer,Sibrand Poppema,Christian Klein,Pablo Umana +24 more
TL;DR: In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival and in nonhuman primates, GA 101 demonstrates superior B cell-depleting activity in lymphoid tissue, including in lymph nodes and spleen.
Journal ArticleDOI
Remission induction in non-hodgkin lymphoma with reshaped human monoclonal antibody campath-1h
G. Hale,Mike Clark,Robert Marcus,Greg Winter,Martin J. S. Dyer,Jenny M. Phillips,Lutz Riechmann,Herman Waldmann +7 more
TL;DR: A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma and might have an important use in the treatment of lymphoproliferative disorders and additionally as an immunosuppressive agent.
Journal ArticleDOI
Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types
Tony G. Willis,Dalal M. Jadayel,Ming-Qing Du,Huaizheng Peng,Amanda R. Perry,Munah Abdul-Rauf,Helen P. Price,Loraine Karran,Oluwatosin Majekodunmi,Iwona Wlodarska,Langxing Pan,Tim Crook,Rifat Hamoudi,Peter G. Isaacson,Martin J. S. Dyer +14 more
TL;DR: MALT B cell lymphomas with t(1;14)(p22;q32) showed a recurrent breakpoint upstream of the promoter of a novel gene, Bcl10, a cellular homolog of the equine herpesvirus-2 E10 gene that contains an amino-terminal caspase recruitment domain (CARD) homologous to that found in several apoptotic molecules.
Journal ArticleDOI
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda,Thomas J. Kipps,Jiří Mayer,Stephan Stilgenbauer,Cathy D. Williams,Andrzej Hellmann,Tadeusz Robak,Richard R. Furman,Peter Hillmen,Marek Trneny,Martin J. S. Dyer,Swami Padmanabhan,Magdalena Piotrowska,Tomas Kozak,Geoffrey W. Chan,Randy Davis,Nedjad Losic,Joris Wilms,Charlotte A. Russell,Anders Österborg +19 more
TL;DR: Ofatumumab is an active, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patients with very poor-prognosis CLL.
Journal ArticleDOI
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A. Johnson,Kerry J. Savage,Olga Ludkovski,Susana Ben-Neriah,Ryan Woods,Christian Steidl,Martin J. S. Dyer,Reiner Siebert,John Kuruvilla,Richard Klasa,Joseph M. Connors,Randy D. Gascoyne,Douglas E. Horsman +12 more
TL;DR: A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL 2-targeted therapy.